Evotec Reports Positive Clinical Trial Results for the repositioning of its CNS-active substance

Hamburg, Germany - Oxford, UK - Evotec AG (German Stock Exchange: EVT,
TecDAX 30) today announced that the study was to reposition its
CNS-active substance (see press release dated 18 March 2005) completed
with positive results.

The clinical trial study in healthy volunteers was performed to
confirm the substance as a potential new drug for the treatment of
insomnia. The preliminary results of this study indicate that the
substance is well tolerated, both in terms of sleep duration and sleep
quality showed significant efficacy. After-effects the following
morning were hardly observed.

Joern Aldag, CEO of Evotec commented: "The positive results of
Repositionierungsstudie us confident to proceed with the clinical
development program, Evotec has the sole commercial rights to the
compound, EVT called 201, which is an essential part of our CNS
development pipeline now.. We are pleased that today our major goal,
the first substance to the end of 2005 to begin the clinical
development, have reached. This is an important step in implementing
our strategy to develop a sustainable CNS pipeline. It shows our
performance in implementing our business model. "

The substance acts on GABA A receptors and has a different
pre-clinical profile of action compared with conventional sleep
medications. It was originally developed by Roche, which was a
clinical phase I study carried out successfully. This is the second
program, Evotec has in-licensed from Roche.

Notes - insomnia

Good and refreshing sleep is a basic requirement for health and
performance. Insomnia patients suffer from a) difficulty falling
asleep; b) staying asleep, ie waking up frequently during the night
with difficulty falling asleep or waking up again in the early morning
hours and c) not a good night's sleep. Approximately 50% of the
population regularly symptoms of insomnia are observed. However, only
a fraction of patients are diagnosed and even fewer using a sleep aid.
However, the market for sleeping pills in the U.S. of U.S. $ 1.4
billion in 2002 to U.S. $ 1.7 billion in 2003, has grown (source:
IMS). According to a Credit Suisse First Boston with leading
therapists sleep study (January 2005), the market for sleeping pills
are still not fully developed and promises sustained growth. The
doctors emphasize that the key success factors lie in the clinic is to
develop new sleeping pills that do not produce residual effects the
next day and no potential dependence and also have the ability to
maintain or improve the quality of sleep. They assume that the market
entry of new drugs with differentiated profiles in terms of dosage,
mode of action and clinical characteristics will accelerate the growth
of the market.

Evotec AG

Evotec is a leader in drug discovery and development. In our own
research programs and through contract research partnerships, the
highest quality research results to its partners in the pharmaceutical
and biotechnology industries. In proprietary projects, Evotec
specializes in finding new therapies for the treatment of diseases of
the central nervous system (CNS). Your drug EVT 201 is used to treat
insomnia in Phase I clinical development. In addition, the company
holds a portfolio of products in late preclinical development. The
most advanced project, EVT 101, a subtype selective NMDA receptor
antagonist for the treatment of Alzheimer's disease, should reach the
end of 2005 into clinical development. In contract research, Evotec
has established itself as a preferred partner for pharmaceutical and
biotechnology companies. The Company provides a fully integrated
offering innovative solutions from drug target to clinic through.
Their services range from providing assay development and screening
through to optimization of chemical substances in medicinal chemistry
and drug manufacturing. With over 600 people in Hamburg, Germany, and
Oxford and Glasgow, UK, Evotec is ideally positioned to carry their
business strategy, the short-and long-term business opportunities
Evotec to create value for partners, shareholders and employees.